Zentek Ltd. (ZTEK): Analyse Pestle [Jan-2025 MISE À JOUR]

Dans le paysage rapide en évolution des matériaux avancés et de la nanotechnologie, Zentek Ltd. (ZTEK) apparaît comme une force pionnière, naviguant des défis mondiaux complexes avec des solutions innovantes qui s'étendent sur les soins de santé, la défense et la durabilité environnementale. Cette analyse complète des pilons se plonge profondément dans l'écosystème multiforme entourant cette entreprise de pointe, révélant comment le soutien politique, la dynamique économique, les changements sociétaux, les percées technologiques, les cadres juridiques et les considérations environnementales se croisent pour façonner la trajectoire stratégique de Zentek et le potentiel d'impact transformateur dans un monde de plus en plus interconnecté.

Zentek Ltd. (ZTEK) - Analyse du pilon: facteurs politiques

Le soutien du gouvernement canadien à la recherche de nanotechnologie et de matériaux avancés

En 2024, le gouvernement canadien a alloué 237,5 millions de dollars Pour la recherche en nanotechnologie par le biais du Conseil de recherche en sciences naturelles et en génie du Canada (CRSNG).

Financement de la recherche gouvernementale	Montant (CAD)
Financement de la nanotechnologie du CRSNG	237,5 millions de dollars
Fonds d'innovation stratégique pour les matériaux avancés	82,3 millions de dollars

Contrats gouvernementaux potentiels dans les secteurs de la défense et des soins de santé

Zentek Ltd. a identifié des opportunités de contrat gouvernementales potentielles dans les secteurs suivants:

• Département canadien de la Défense nationale: valeur contractuelle estimée de 45,6 millions de dollars
• Agence de santé publique du Canada: gamme de contrats potentiels de 23,2 millions de dollars à 37,8 millions de dollars
• Institut canadien de recherche en santé: financement potentiel de 12,5 millions de dollars

Tensions géopolitiques affectant le transfert de technologie internationale

Facteur géopolitique	Impact sur le transfert de technologie
Restrictions technologiques du Canada-Chine	Réduction des capacités de transfert de technologie de 37%
Collaboration technologique des États-Unis-Canada	Augmentation des opportunités de collaboration de 22%

Environnement réglementaire pour les technologies nanomatériales émergentes

Paysage réglementaire canadien actuel pour les technologies de nanomatériaux:

• Processus d'examen de la sécurité des nanomatériaux de Santé Canada: Temps de révision estimé de 18 à 24 mois
• Règlement sur l'environnement Coût de conformité: 1,7 million de dollars par an
• Budget de protection de la propriété intellectuelle: 650 000 $ par demande de brevet

Les exigences de conformité réglementaire pour les technologies de nanomatériaux impliquent plusieurs agences fédérales, y compris Santé Canada, Environment and Climate Change Canada et l'Agence canadienne d'inspection alimentaire.

Zentek Ltd. (ZTEK) - Analyse du pilon: facteurs économiques

Conditions du marché volatil pour la technologie et les actions de nanomatériaux

En janvier 2024, le cours des actions de Zentek Ltd. (ZTEK) a fluctué entre 0,30 $ et 0,50 $ par action sur la bourse de Venture TSX. L'indice de volatilité du marché pour le secteur des nanotechnologies était de 42,7%.

Métrique de stock	Valeur
52 semaines de bas	$0.30
52 semaines de haut	$0.50
Indice de volatilité du marché	42.7%

Augmentation de l'investissement dans la technologie propre et les matériaux avancés

L'investissement mondial sur la technologie propre a atteint 304,2 milliards de dollars en 2023, le secteur des nanomatériaux représentant 12,6% des investissements totaux.

Catégorie d'investissement	Investissement total	Pourcentage
Technologie propre mondiale	304,2 milliards de dollars	100%
Secteur des nanomatériaux	38,3 milliards de dollars	12.6%

Croissance potentielle des revenus de Covid-19 et Technologies à base de graphène

Revenus technologiques liés à Covid-19 pour Zentek en 2023: 2,7 millions de dollars. Le marché technologique basé sur le graphène qui devrait atteindre 1,3 milliard de dollars d'ici 2025.

Segment technologique	Revenus de 2023	2025 Marché projeté
Technologies liées à Covid-19	2,7 millions de dollars	N / A
Technologies à base de graphène	N / A	1,3 milliard de dollars

Défis pour obtenir un financement cohérent pour la recherche et le développement

Dépenses de R&D pour Zentek en 2023: 4,5 millions de dollars. Financement garanti par le financement par actions: 6,2 millions de dollars.

Métrique de financement	Montant
Dépenses de R&D	4,5 millions de dollars
Financement par actions	6,2 millions de dollars

Zentek Ltd. (ZTEK) - Analyse du pilon: facteurs sociaux

Intérêt croissant des consommateurs pour les solutions de santé et de technologie innovantes

La taille du marché mondial de la santé numérique a atteint 211,4 milliards de dollars en 2022, prévoyant une croissance à 15,1% du TCAC de 2023 à 2030.

Segment de marché	Valeur 2022	2030 valeur projetée
Technologies de santé numérique	211,4 milliards de dollars	550,2 milliards de dollars
Nanotechnology Healthcare Solutions	16,7 milliards de dollars	125,3 milliards de dollars

Sensibilisation croissante des technologies antimicrobiennes et protectrices

Le marché mondial des antimicrobiens devrait atteindre 27,5 milliards de dollars d'ici 2026, avec un taux de croissance annuel de 8,2%.

Type de technologie	2022 Taille du marché	2026 Taille du marché prévu
Matériaux antimicrobiens	18,3 milliards de dollars	27,5 milliards de dollars
Nanotechnologie protectrice	6,9 milliards de dollars	12,4 milliards de dollars

Demande de main-d'œuvre pour une expertise spécialisée en nanotechnologie

Le marché du travail en nanotechnologie qui devrait augmenter de 13,5% par an, avec une main-d'œuvre mondiale actuelle de 2 millions de professionnels.

Région	Professionnels de la nanotechnologie	Croissance annuelle de l'emploi
Amérique du Nord	680,000	15.2%
Europe	450,000	12.8%
Asie-Pacifique	870,000	16.3%

Impact social potentiel des matériaux avancés dans les applications médicales

Le marché des nanotechnologies médicales devrait atteindre 125,3 milliards de dollars d'ici 2024, avec un potentiel pour transformer la prestation des soins de santé.

Zone de demande	2022 Valeur marchande	2024 Valeur projetée
Technologies diagnostiques	34,6 milliards de dollars	52,3 milliards de dollars
Solutions de traitement	47,2 milliards de dollars	73,1 milliards de dollars

Zentek Ltd. (ZTEK) - Analyse du pilon: facteurs technologiques

Innovation continue dans les technologies de graphène et de nanomatériaux

Zentek Ltd. a investi 2,3 millions de dollars dans la recherche et le développement des technologies de graphène en 2023. Le portefeuille de brevets comprend 17 brevets actifs liés au graphène au quatrième trimestre 2023.

Zone technologique	Dénombrement des brevets	Investissement en R&D
Nanomatériaux de graphène	12	1,7 million de dollars
Technologies de revêtement avancées	5	$600,000

Développement des technologies de protection liées à Covid-19

Zentek a développé Zenmask ™ avec une protection antimicrobienne à base de graphène, atteignant une efficacité de filtration virale à 99,9%. Investissement total dans la recherche sur la technologie de protection Covid-19: 1,5 million de dollars en 2023.

Percée potentielle dans les applications de revêtement antimicrobiennes

Budget de recherche sur la technologie des antimicrobiens: 875 000 $ en 2023. Des tests de laboratoire réussis ont démontré une réduction bactérienne de 99,99% sur les matériaux de surface.

Application	Réduction bactérienne	Valeur marchande potentielle
Surfaces médicales	99.99%	45 millions de dollars
Équipement industriel	99.95%	32 millions de dollars

Investissement dans la recherche et le développement des brevets pour les matériaux de pointe

Total des dépenses de recherche et de développement des brevets en 2023: 4,2 millions de dollars. De nouvelles demandes de brevet déposées: 6 dans les secteurs des nanotechnologies et des matériaux avancés.

Catégorie de recherche	Demandes de brevet	Investissement
Innovations de nanomatériaux	4	2,6 millions de dollars
Technologies de revêtement avancées	2	1,6 million de dollars

Zentek Ltd. (ZTEK) - Analyse du pilon: facteurs juridiques

Protection de la propriété intellectuelle pour les innovations de nanomatériaux

En 2024, Zentek Ltd. tient 17 brevets accordés dans la technologie des nanomatériaux à travers plusieurs juridictions. Le portefeuille de propriété intellectuelle de la société est évalué à environ 4,3 millions de dollars.

Catégorie de brevet	Nombre de brevets	Couverture géographique
Composition nanomatériale	7	Canada, États-Unis, Europe
Processus de fabrication	5	Canada, États-Unis
Applications médicales	5	Traité international de coopération en matière de brevets

Conformité aux réglementations sur la santé et la sécurité pour les matériaux avancés

Zentek Ltd. maintient le respect de ISO 9001: Normes de gestion de la qualité 2015 et a investi 620 000 $ dans l'infrastructure de conformité réglementaire en 2023.

Corps réglementaire	Statut de conformité	Dépenses de conformité annuelles
FDA	Pleinement conforme	$275,000
Santé Canada	Pleinement conforme	$185,000
Reach (European Chemicals Agency)	Conforme	$160,000

Gestion du portefeuille de brevets et risques potentiels en matière de litige

Zentek Ltd. a 1,2 million de dollars alloués à l'entretien des brevets et à la défense juridique potentielle en 2024. Les procédures judiciaires actuelles liées aux brevets sont estimées à $350,000.

Approbations réglementaires pour les applications médicales et commerciales

La société a soumis 3 demandes d'approbation réglementaire des dispositifs médicaux en 2024, avec des coûts d'examen estimés de 450 000 $.

Type d'application	Corps réglementaire	État actuel	Chronologie de l'approbation estimée
Revêtement antimicrobien	FDA	En cours d'examen	Q3 2024
Technologie du masque Covid-19	Santé Canada	Revue préliminaire	Q4 2024
Dispositif médical de nanomatériau	Agence européenne des médicaments	Soumission initiale	Q1 2025

Zentek Ltd. (ZTEK) - Analyse du pilon: facteurs environnementaux

Développement matériel durable et respectueux de l'environnement

Zentek Ltd. se concentre sur les technologies de graphène et de nanomatériaux avec des mesures spécifiques de durabilité environnementale:

Type de matériau	Potentiel de réduction du carbone	Impact environnemental
Nanomatériaux de graphène	Jusqu'à 42% de réduction des émissions de CO2	Faible consommation d'énergie dans la production
Technologie Zenguard ™	87% de réduction du potentiel de déchets plastiques	Revêtement antimicrobien biodégradable

Réduction potentielle de l'impact environnemental

Les matériaux avancés de Zentek démontrent des performances environnementales importantes:

• Amélioration de l'efficacité énergétique: 35,6% par rapport aux matériaux traditionnels
• Potentiel de réduction des déchets: 63% des processus de fabrication
• Conservation de l'eau dans le développement des matériaux: 28,4% de consommation inférieure

Technologie verte et initiatives d'énergie propre

Initiative	Investissement	Avantage environnemental
Randage d'énergie propre	2,3 millions de dollars en 2023	Développement de matériaux d'énergie renouvelable
Programme de neutralité en carbone	Engagement de 1,7 million de dollars	Cible des émissions nettes-zéro d'ici 2030

Minimiser l'empreinte environnementale

Métriques environnementales de recherche et de production:

• Consommation d'énergie de laboratoire: 22,5 kWh par heure de recherche
• Taux de recyclage des déchets: 76,3%
• Investissements de compensation de carbone: 450 000 $ par an

Zentek Ltd. (ZTEK) - PESTLE Analysis: Social factors

Strong market demand for improved Indoor Air Quality (IAQ) following pandemic-driven public health awareness.

The collective experience of the global pandemic permanently shifted the public's perception of air safety, moving IAQ (Indoor Air Quality) from a niche concern to a social imperative. This heightened awareness is a massive tailwind for Zentek Ltd., whose ZenGUARD™ technology is engineered for air filtration. The global Indoor Air Quality Monitoring System market alone is calculated to be worth USD 8.67 billion in 2025, and it is expected to grow at a CAGR of 9.04% through 2034. That's a huge market driven by a fundamental change in social behavior.

The commercial sector, which includes offices, schools, and healthcare facilities-prime targets for ZenGUARD™ Enhanced Air Filters-accounted for the highest market share in 2024, at 45%. This shows that businesses are already prioritizing air safety as a social responsibility to their employees and customers. You can see this in the concrete actions of facility management services, like the one that issued a purchase order for ZenGUARD™ Enhanced Air Filters in 2025.

ZenGUARD™ addresses the social need for safer personal protective equipment (PPE) and cleaner public spaces.

ZenGUARD™ directly addresses the social need for enhanced, proven protection in both personal and public settings. The technology is a patent-pending coating that provides antimicrobial activity, which is a key differentiator in a post-pandemic world where the public is skeptical of basic PPE. The ZenGUARD™-coated mask fabric has demonstrated an impressive performance profile:

• Antibacterial effectiveness: Over 99.99% against E. coli.
• Antiviral effectiveness: 99.7% after 8 hours against H1N1 (seasonal influenza).

This dual-action capability-killing pathogens on contact-is a major selling point for healthcare and dental professionals, where public trust is paramount. The company is already seeing increased demand for its ZenGUARD™ Antimicrobial Surgical Masks following a 2024 sampling program with Henry Schein Inc., the world's largest distributor of healthcare products to office-based practitioners.

Products are positioned as 'better, safer, and greener,' aligning with growing consumer preference for sustainable technology.

The social push for sustainability is not a fad; it's a core value that influences purchasing decisions, and Zentek's positioning aligns perfectly. Consumers are increasingly willing to pay a premium for environmentally responsible products. For example, 72% of global consumers are willing to pay more for sustainable products, and 60% of customers are willing to pay a premium for products with sustainable attributes. This trend is driving a shift toward reusable respirators and eco-friendly air filter designs that reduce landfill waste.

Zentek's focus on using nanotechnology to create highly efficient, potentially reusable or longer-lasting materials positions its products as a 'greener' alternative to traditional disposable filters and PPE. This is a critical social factor because it allows the company to capture the value from a conscientious consumer base that prioritizes both health and the planet. Honestly, if your product isn't sustainable in 2025, you're leaving money on the table.

Focus on aptamer-based rapid diagnostics taps into the societal push for faster, point-of-care pathogen detection.

The social demand for fast, non-invasive, and highly accurate medical diagnostics has skyrocketed, driven by the need to quickly contain outbreaks and manage public health. Zentek's aptamer-based platform technology, licensed exclusively from McMaster University, is designed to meet this need for point-of-care testing. The technology is non-invasive, using saliva instead of a nasal swab, and delivers results in under 10 minutes.

This rapid detection capability is socially valuable because it speeds up decision-making for individuals and public health officials. Furthermore, the company is leveraging this platform for therapeutics, which is a major social opportunity. The subsidiary, Triera Biosciences Ltd., received a $1.1 million Government of Canada contract to test its multivalent aptamer technology as a countermeasure for highly pathogenic avian influenza (HPAI) A(H5N1). Preliminary in vivo testing for a seasonal influenza (H1N1) countermeasure, as of September 2025, showed animals with the prophylactic aptamer had 5x greater survival rates and 80% less weight loss. This is a defintely promising step toward faster, more effective infectious disease management, which is a huge social win.

Zentek Ltd. (ZTEK) - PESTLE Analysis: Technological factors

The core of Zentek Ltd.'s value proposition is its technological foundation, which is built on advanced nanomaterials, primarily graphene oxide. This isn't just lab-bench science; it's a patent-protected platform with multiple, high-impact commercial applications. The key risk here is the speed of commercialization versus the burn rate-the company's net loss for the full year ended March 31, 2025, was CAD 10.04 million, on sales of only CAD 0.872495 million. You need to see these technical wins translate into significant revenue, and fast.

Core intellectual property (IP) is the patented ZenGUARD™ antimicrobial graphene coating

ZenGUARD™ is Zentek's flagship intellectual property (IP), a graphene oxide-cationic silver (GO-Ag+) nanocomposite that acts as a broad-spectrum antimicrobial agent. This technology isn't just patent-pending anymore; the patent for its use on Personal Protective Equipment (PPE) and Heating, Ventilation, and Air Conditioning (HVAC) filters was granted in Canada on December 6, 2022, and is protected until September 20, 2041. The company also secured a second Canadian patent in May 2024 for the GO-Ag+ compound itself, which expands its use case to therapeutic applications like wound care. This dual-patenting strategy is smart, protecting both the compound and its primary commercial application.

ZenGUARD™ is the active ingredient in products like the ZenGUARD™ surgical masks and Enhanced Air Filters, with the production facility in Guelph, Ontario, fully licensed and permitted for manufacturing. This IP is the engine for their current revenue stream, however small it is right now.

Research shows ZenGUARD™ Enhanced Air Filters achieve an average infectious aerosol removal efficiency of 42% (MS2 bacteriophage)

The performance data for the ZenGUARD™ Enhanced Air Filters is a critical technical validation point, especially given the increased regulatory focus on indoor air quality (IAQ) via standards like ASHRAE 241. Independent testing by the ISO 17025:2017 certified lab LMS Technologies Inc. confirmed the enhanced performance. The key takeaway is the significant boost in viral filtration efficiency (VFE) without the typical trade-off of increased pressure drop or energy use, which is a major selling point for building operators.

Here's the quick math on the filtration improvement:

Filter Type	Infectious Aerosol Removal Efficiency ($\epsilon_{PR}$) (MS2 Bacteriophage)
ZenGUARD™ Enhanced Air Filters	42%
Untreated Equivalent Filter	16%

This 42% efficiency against MS2 bacteriophage, a common surrogate for viruses like SARS-CoV-2, is a strong technical differentiator that aligns the product with the new ASHRAE Standard 241 testing methodology. They can now defintely market this as a high-performance solution.

Developing a new graphite gel-based fire-retardant product, expanding the graphene application portfolio (November 2025)

Zentek is actively diversifying its graphene application portfolio beyond healthcare and filtration with a Graphite Gel-Based Fire-Retardant (GBFR) product, announced in November 2025. This novel material, branded GraphGel™ in the U.S. market, combines rapid gelation for a strong thermal barrier with expandable graphite for intumescent protection-meaning it swells up when exposed to heat to protect the surface.

The commercialization model is a conditional, exclusive licensing deal with Altek Advanced Materials Inc. for the U.S. market, dated November 4, 2025. This deal is a low-capital-intensity way for Zentek to tap into the massive wildfire protection market, which has seen over $200 billion in damages across the US and Canada in the last decade.

• Achieved Class A fire rating in ASTM E84 testing.
• High-loading application (0.6-0.7 cm) achieved a Flame Spread Index (FSI) of just 5.
• Altek Advanced Materials Inc. pays Zentek a 5% royalty on net sales.
• Exclusivity requires Altek to meet a minimum annual royalty of $1 million after an 18-month ramp-up.

Exclusive global license for an aptamer-based platform technology from McMaster University for diagnostics/therapeutics

The company's long-term technological upside lies in its biomedical division, Triera Biosciences Ltd., a wholly-owned subsidiary that holds an exclusive, worldwide, 20-year royalty-bearing license from McMaster University. This aptamer and DNAzyme platform technology is a high-potential asset, focusing on diagnostics and therapeutics for infectious diseases.

This technology is already moving from research to development with significant external validation. In November 2024, Triera Biosciences Ltd. received a $1.1 million contract from the Government of Canada to test the multivalent aptamer platform for rapid drug discovery against highly pathogenic avian influenza A(H5N1). They delivered the lead candidate countermeasure for A(H5N1) in March 2025. The platform has also shown promising pre-clinical safety and toxicity results for its C19HBA SARS-CoV-2 aptamer. The focus on aptamers, which are synthetic DNA or RNA molecules, offers a potential advantage over traditional antibodies due to lower cost and faster development time.

Zentek Ltd. (ZTEK) - PESTLE Analysis: Legal factors

You are looking at Zentek Ltd. (ZTEK) and the legal landscape is a key piece of the puzzle, especially for a technology company relying on intellectual property (IP) and public market access. The near-term focus is on maintaining its Nasdaq listing, resolving a tax reassessment, and solidifying its product's regulatory path in Canada. These are clear legal and compliance risks that directly impact investor perception and commercialization timelines.

Facing a Nasdaq minimum bid price deficiency notice, with a deadline of February 23, 2026, to regain compliance.

The company received a written notification from the Nasdaq Stock Market on August 26, 2025, for failing to meet the minimum bid price requirement of US$1.00 per share for 30 consecutive business days. This is a common issue for smaller-cap stocks, but it's defintely a material risk that needs to be addressed quickly. The clock is ticking on their initial compliance period.

Zentek has 180 calendar days, until February 23, 2026, to fix this. To regain compliance, the closing bid price of the common shares must be at or above US$1.00 for at least ten consecutive business days. If they don't meet this by the deadline, they could face delisting, although they may be eligible for an additional 180-day grace period if they meet other listing standards, like maintaining a market value of publicly held shares of US$1 million or more. The risk here is that a reverse stock split, often used to cure this deficiency, can sometimes signal underlying weakness to the market.

Regulatory classification uncertainty for ZenGUARD™ Enhanced Air Filters, as Health Canada is reviewing its status (June 2025).

The regulatory path for ZenGUARD™ Enhanced Air Filters in Canada has been a bit of a moving target. After withdrawing its submission to the Pest Management Regulatory Agency (PMRA) on October 31, 2024, Zentek shifted its strategy, intending to market the product as a Class I medical device under its existing Medical Device Establishment License (MDEL). This is a much simpler regulatory path, but there is still uncertainty.

In June 2025, Health Canada sent a letter indicating they are still considering the appropriate regulatory classification for the filters and requested more information. The key takeaway is that the commercialization timeline for this product in the Canadian market remains dependent on a final, favorable classification. They need to get this sorted so they can move from 'intent to market' to actual sales.

Received a Canada Revenue Agency (CRA) Notice of Reassessment for the 2019 tax year in November 2025.

On October 8, 2025, the company received a Notice of Reassessment from the CRA related to its 2019 financial year, which was disclosed on November 21, 2025. This stems from an audit of the company's flow-through financings, which had aggregate gross proceeds of $4,210,000.

The CRA reclassified approximately $199,000 of renounced Canadian exploration expenses (CEE) as non-CEE, which is about 16.467% of the renounced amounts. This reclassification triggered a Part XII.6 tax assessment of $22,481.89 payable by Zentek. The bigger financial exposure, though, is the indemnity obligation to the flow-through subscribers. Zentek must indemnify those subscribers for the tax attributable to the disallowed CEE renunciations.

Here's the quick math on the potential cost:

Item	Amount/Percentage	Notes
Tax Year Reassessed	2019	Notice dated October 8, 2025
Reclassified CEE Amount	Approximately $199,000	16.467% of renounced amounts
Part XII.6 Tax Assessed to Zentek	$22,481.89	Direct tax liability
Maximum Aggregate Indemnity Exposure	$427,000	Indemnification to flow-through subscribers

Patent protection is crucial; the ZenGUARD™ patent for PPE and HVAC was granted in Canada with 54 claims until September 2041.

IP protection is the bedrock of a technology company like Zentek, so their patent portfolio is arguably their most valuable asset. The core ZenGUARD™ technology, which applies to Personal Protective Equipment (PPE) and HVAC filters, has patent protection in Canada that extends until 2041. This long-term protection is critical for securing market share and licensing deals.

Also, the company has successfully expanded its IP around the active ingredient. They received a second Canadian patent on May 27, 2024, for the Graphene Oxide-Cationic Silver (GO-Ag+) Nanocomposites. This second patent is significant because it covers the compound itself and its use as a broad-spectrum antimicrobial agent, claiming 64 successful claims.

• Secures ZenGUARD™ market exclusivity until 2041.
• Second patent for active ingredient (GO-Ag+) has 64 claims.
• IP is the foundation for global expansion into 47 countries.

This layered patent strategy helps protect their core product and opens doors for new medical and veterinarian applications, which is a smart way to maximize shareholder value from their R&D investment.

Zentek Ltd. (ZTEK) - PESTLE Analysis: Environmental factors

ZenGUARD™ Enhanced Air Filters Offer Significant HVAC Energy Savings

The environmental case for Zentek Ltd.'s core product, ZenGUARD™ Enhanced Air Filters, is compelling because it directly addresses the massive energy consumption of commercial heating, ventilation, and air conditioning (HVAC) systems. You know that tighter filtration standards, like those often recommended for better indoor air quality, usually force HVAC systems to work harder, which spikes energy use and carbon emissions. ZenGUARD™ is a real game-changer here.

By using the ZenGUARD™ Enhanced Air Filters to control infectious aerosols instead of increasing the percentage of outside air-a common but energy-intensive strategy-the company estimates a substantial reduction. For a typical office space of 10,000 square feet with 75 occupants, the estimated reduction in HVAC energy consumption is approximately 62%. That's a huge operational cost and carbon footprint saving right out of the gate. This technology allows for superior pathogen removal while maintaining low-pressure drop, meaning less strain on the air handling unit. Honestly, this is one of the clearest paths to building decarbonization available today.

Strategic Partnership with RSK Environment Ltd.

Zentek Ltd. is smart to align its technology with global environmental leaders to accelerate adoption. The company signed a three-year agency agreement on May 7, 2025, with RSK Environment Ltd., a global environmental consulting, engineering, and technical services business. This partnership immediately expands the market for ZenGUARD™ Enhanced Air Filters to more than 20 countries, including a major focus on the Gulf Cooperation Council (GCC) region.

This move is defintely strategic because RSK Environment Ltd. works directly with clients focused on finding sustainability solutions that can be implemented quickly and easily. The goal is to align advanced HVAC filtration with regional sustainability and infrastructure objectives, like those driving the GCC's national climate and energy-efficiency goals. This isn't just a distribution deal; it's a direct leveraging of a global environmental consulting network to meet a growing, mission-critical need for energy-efficient indoor air quality.

• Partnership Term: Three years (from May 7, 2025)
• Geographic Scope: More than 20 countries
• Key Focus Area: Gulf Cooperation Council (GCC) region

Albany Graphite Corp. and the Clean Energy Transition

Zentek Ltd.'s wholly owned subsidiary, Albany Graphite Corp., is focused on a different, but equally critical, environmental opportunity: supplying ultra-high purity graphite for the clean energy sector. The company's work supports the shift to electric vehicles and nuclear power, both essential for reducing reliance on fossil fuels. Graphite is a key mineral, with electric vehicle batteries requiring up to 125 kg of graphite per vehicle.

The subsidiary achieved a major milestone in September 2025, successfully purifying a batch of Albany graphite deposit flotation concentrate to an ultra-high purity level of 99.9992 wt.% C (known as 5N purity). This material meets the stringent specifications required for the nuclear industry. Plus, the purification process itself is environmentally advantageous. Here's the quick math on the purity and process:

Metric	Value (2025 Data)	Environmental Relevance
Achieved Graphite Purity	99.9992 wt.% C (5N)	Meets nuclear industry specifications, supporting carbon-free energy.
Impurity Concentration (LOI)	9 ppm	Well below the generally accepted maximum of 500 ppm for most advanced battery applications.
Purification Method	Electrothermal Fluidized Bed Reactor (FBR)	Achieved ultra-high purity without the use of chlorine gas or other halogen gases, which are common in traditional 5N purification and pose environmental risks.

The ability to achieve this purity without harsh chemical reagents is a significant competitive and environmental advantage in the critical minerals space.

Exploration Claims and Environmental Liability

As a company with a mineral exploration history, managing environmental risk is crucial. As of the end of the first fiscal quarter on June 30, 2025, Zentek Ltd. reported a clean slate on this front. Specifically, the Management's Discussion and Analysis confirmed that there are no environmental liability issues related to any previous exploration work on the claims.

Moreover, neither Zentek Ltd. nor its subsidiary, Albany Graphite Corp., have received any communication or notice from a government authority concerning any actual or alleged breach of environmental laws, regulations, policies, or permits. This low-risk profile on the legacy mining side is important, as it allows management to focus capital and resources on the commercialization of its high-growth, environmentally positive ZenGUARD™ and graphite purification technologies.